Skip to main content

Table 3 Measures of Impairment and Perception

From: Quality of life in adults with muscular dystrophy

  DMD BMD LGMD FSHD CTRL
KEMVC (N.m) 12.6 ± 8.8 B***,LG***,F***,C*** 96.6 ± 60.0 C** 98.2 ± 56.4 C* 123.6 ± 78.2 164.6 ± 55.9
CIS Severity 34.4 ± 8.7 F*,C*** 33.2 ± 10.5 F**,C*** 34.4 ± 10.9 C*** 43.0 ± 5.3 C*** 14.1 ± 6.1
VAS Pain 2.5 ± 1.6 C** 3.5 ± 2.5 C*** 3.6 ± 2.8 C*** 3.9 ± 2.2 C*** 0.4 ± 0.7
NEADL 13.9 ± 6.0 B***,LG*,F***,C*** 36.7 ± 14.4C*** 29.3 ± 7.1 C*** 39.4 ± 14.6C** 63.6 ± 3.1
Self-Efficacy 31.0 ± 6.2 28.3 ± 5.9 31.0 ± 5.1 30.7 ± 7.5 34.3 ± 4.3
  1. Measures of Impairment and Perception
  2. DMD Duchenne Muscular Dystrophy, BMD Beckers Muscular Dystrophy, LGMD Limb-Girdle Muscular Dystrophy, FSHD Facioscapulohumeral Muscular Dystrophy, CIS Checklist Individual Strength, VAS Visual Analog Scale, KEMVC Knee Extension Maximal Voluntary Contraction, N.m Newton Metres, NEADL Nottingham Extended Activities of Daily Living; B denotes significant difference from BMD; LG denotes significant difference from LGMD; F denotes significant difference from FSHD; C denotes significant difference from CTRL; * denotes significance P < .05; ** denotes significance P < .01; *** denotes P < .001